| Assessment Status |
Rapid Review Complete |
| HTA ID |
23008 |
| Drug |
House dust mite allergen extract |
| Brand |
Actair® |
| Indication |
Dermatophagoides pteronyssinus and Dermatophagoides farinae in equal parts (Actair®) is indicated for the treatment of moderate-to-severe house dust mite (HDM)–induced allergic rhinitis (AR) or rhinoconjunctivitis diagnosed by clinical history and a positive test of HDM sensitisation (skin prick test [SPT] and/or specific immunoglobulin E [IgE]) in adolescents (aged 12-17 years) and adults. |
| Rapid review commissioned |
10/02/2023 |
| Rapid review completed |
24/02/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM allergen extracts compared with the current standard of care. |
